(Q33398044)

26 July 2017

title

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes (English)

1 reference

26 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

4

Pierre Fenaux

1 reference

26 July 2017

Antonio Palumbo

1

1 reference

26 July 2017

John Freeman

series ordinal

2

1 reference

26 July 2017

Lilia Weiss

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 November 2011

1 reference

Expert Opinion on Drug Safety

26 July 2017

published in

1 reference

26 July 2017

volume

11

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

107-120

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Risky business in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Meeting the unmet needs in anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Thalidomide for treatment of multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.619975

10.1517/14740338.2011.619975

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference